MRK
Merck & Company Inc
142.80$
+0.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.3% | 1.7% | 19.6% | 35.0% | 55.8% | 22.1% | 16.0% | 20.8% | 45.5% | 17.5% | 24.1% | 32.3% | 30.1% | |
| 6.4% | 6.6% | 6.2% | 7.0% | 7.1% | 7.7% | 7.0% | 7.1% | 6.7% | 8.7% | 9.3% | 9.5% | 8.5% | |
| 1.0% | 1.1% | 1.1% | 1.3% | 1.2% | 1.2% | 1.2% | 1.4% | 1.2% | 1.3% | 1.1% | 1.8% | 1.3% | |
| -1.1% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 13.6% | 1.0% | -21.4% | -6.3% | 15.5% | -11.9% | -23.8% | -14.3% | 7.6% | -15.7% | -9.9% | 9.7% | -1.9% | |
| 5.7% | 6.8% | 5.5% | 4.9% | 4.7% | 6.0% | 8.5% | 4.8% | 5.7% | 6.3% | 6.1% | 5.4% | 5.9% | |
| -2.1% | 0.4% | -8.7% | -6.6% | -23.1% | -9.2% | -9.5% | -4.9% | -1.6% | -68.6% | -62.7% | -33.7% | -41.1% | |
| 11.6% | 12.7% | 12.4% | 12.3% | 11.7% | 12.5% | 13.1% | 13.1% | 11.8% | 12.4% | 12.9% | 12.9% | 12.5% | |
| -2.9% | -2.7% | -0.8% | -1.6% | -2.7% | -3.1% | -7.5% | -8.5% | 14.5% | -7.7% | -5.4% | -4.6% | -0.6% | |
| -12.2% | – | – | – | 0.0% | -3.4% | -16.0% | 0.3% | 34.8% | 48.1% | -0.5% | 29.4% | 28.1% | |
| -26.7% | -15.3% | -17.8% | 7.5% | -14.6% | -19.3% | -36.8% | -22.5% | 15.4% | 29.1% | -18.3% | 10.6% | 9.3% | |
| 18.5% | -12.0% | -7.8% | 35.4% | 19.9% | -8.8% | -29.4% | -4.2% | 59.3% | -21.5% | -57.1% | 9.0% | -1.7% | |
| 42.7% | -5.1% | 14.1% | 30.1% | 51.1% | 16.1% | 7.5% | 16.0% | 39.8% | 11.2% | 18.0% | 27.0% | 24.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.